B. Sangro
Impact in
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
-
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Hepatology 14
- Hepatocellular Carcinoma Treatment and Prognosis 14
- Oncology 2
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Masatochi Kudo (6 shared papers)Michael Jonathan Paskow (2 shared papers)Masatoshi Kudo (2 shared papers)Stephen Lam Chan (6 shared papers)Corinne Emery (1 shared paper)Ghassan K. Abou-Alfa (3 shared papers)Mallory Makowsky (4 shared papers)Lorenza Rimassa (2 shared papers)
- Journals
- Annals of Oncology (14 papers)Revista de medicina de la Universidad de Navarra (2 papers)
- Partner nations
- SpainUnited StatesJapan
In The Last Decade
B. Sangro
12 papers receiving 321 citations
B. Sangro's Hit Papers
Peers
Comparison fields: 5 of 19
- Hepatology 252
- Oncology 96
- Immunology 9
- Cancer Research 6
- Toxicology 2
Countries citing papers authored by B. Sangro
This map shows the geographic impact of B. Sangro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Sangro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Sangro more than expected).
Fields of papers citing papers by B. Sangro
This network shows the impact of papers produced by B. Sangro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Sangro. The network helps show where B. Sangro may publish in the future.
Co-authors
The 25 scholars most cited alongside B. Sangro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma Hit paper breakdown → | 2024 | 239 |
| 2 | 2024 | 59 | |
| 3 | 2022 | 6 | |
| 4 | 2023 | 5 | |
| 5 | 2024 | 5 | |
| 6 | 2025 | 3 | |
| 7 | 2022 | 2 | |
| 8 | 2023 | 2 | |
| 9 | 2024 | 2 | |
| 10 | 2017 | 1 | |
| 11 | 2025 | 1 | |
| 12 | 2025 | 1 | |
| 13 | 2017 | 0 | |
| 14 | 2025 | 0 | |
| 15 | 2025 | 0 | |
| 16 | 2026 | 0 |
About B. Sangro
B. Sangro is a scholar working on Hepatology, Oncology, Rheumatology, Immunology and Nuclear Energy and Engineering, having authored 16 papers that have together received 326 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Immunotherapy and Biomarkers (2 papers), Immunotherapy and Immune Responses (1 paper) and Systemic Lupus Erythematosus Research (1 paper). The work is most often cited by research in Hepatology (252 citations), Oncology (96 citations), Immunology (9 citations), Cancer Research (6 citations) and Toxicology (2 citations). B. Sangro has collaborated with scholars based in Spain, United States and Japan. Frequent co-authors include Masatochi Kudo, Michael Jonathan Paskow, Masatoshi Kudo, Stephen Lam Chan, Corinne Emery, Ghassan K. Abou-Alfa, Mallory Makowsky, Lorenza Rimassa, Aaron L. Dane and Qi Wang. Their work appears in journals such as Annals of Oncology and Revista de medicina de la Universidad de Navarra.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.